Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DGZ38L
|
|||
| Drug Name |
NK314
|
|||
| Synonyms |
208237-49-4; 1-hydroxy-2-methoxy-11a,13,14,15-tetrahydro-6aH-[1,3]dioxolo[4',5':4,5]benzo[1,2-c]pyrrolo[1,2-f]phenanthridin-12-ium chloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | T-cell leukaemia [ICD-11: 2A90; ICD-10: C86] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C22H20ClNO4
|
|||
| Canonical SMILES |
COC1=C(C2=C3CCC[N+]3=C4C5C=C6C(=CC5C=CC4=C2C=C1)OCO6)O.[Cl-]
|
|||
| InChI |
1S/C22H19NO4.ClH/c1-25-17-7-6-13-14-5-4-12-9-18-19(27-11-26-18)10-15(12)21(14)23-8-2-3-16(23)20(13)22(17)24;/h4-7,9-10,12,15H,2-3,8,11H2,1H3;1H
|
|||
| InChIKey |
YLNMBOMTXKNYDO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase II alpha (TOP2A) | Target Info | Inhibitor | [2] |
| NetPath Pathway | TCR Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| Panther Pathway | DNA replication | |||
| Pathway Interaction Database | Validated transcriptional targets of deltaNp63 isoforms | |||
| Reactome | G0 and Early G1 | |||
| WikiPathways | Retinoblastoma (RB) in Cancer | |||
| Integrated Pancreatic Cancer Pathway | ||||
| Gastric cancer network 2 | ||||
| Gastric Cancer Network 1 | ||||
| Mitotic G1-G1/S phases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase. Blood. 2011 Mar 31;117(13):3575-84. | |||
| REF 2 | NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.